67 related articles for article (PubMed ID: 20674019)
1. The role of p53 and autophagy in Dasatinib resistance of CLL lymphocytes.
Pitini VV
Leuk Res; 2011 Jan; 35(1):32-3. PubMed ID: 20674019
[No Abstract] [Full Text] [Related]
2. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.
Amrein L; Soulières D; Johnston JB; Aloyz R
Leuk Res; 2011 Jan; 35(1):99-102. PubMed ID: 20573397
[TBL] [Abstract][Full Text] [Related]
3. On the assessment of dasatinib-induced autophagy in CLL.
Krause G; Hallek M
Leuk Res; 2011 Jan; 35(1):137-8. PubMed ID: 20947165
[No Abstract] [Full Text] [Related]
4. Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
Tecchio C; Nichele I; Todeschini G; Pizzolo G; Ambrosetti A
Br J Haematol; 2009 Jul; 146(2):222-3. PubMed ID: 19466973
[No Abstract] [Full Text] [Related]
5. Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy.
Russwurm G; Heinsch M; Radkowski R; Erlemann R; Aul C; Haase S; Giagounidis A
Blood; 2010 Oct; 116(14):2617-8. PubMed ID: 20930084
[No Abstract] [Full Text] [Related]
6. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
Amrein PC; Attar EC; Takvorian T; Hochberg EP; Ballen KK; Leahy KM; Fisher DC; Lacasce AS; Jacobsen ED; Armand P; Hasserjian RP; Werner L; Neuberg D; Brown JR
Clin Cancer Res; 2011 May; 17(9):2977-86. PubMed ID: 21402714
[TBL] [Abstract][Full Text] [Related]
7. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Pettitt AR; Sherrington PD; Cawley JC
Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?
D'Arena G; Gemei M; Luciano L; D'Auria F; Deaglio S; Statuto T; Bianchino G; Grieco V; Mansueto G; Guariglia R; Pietrantuono G; Martorelli MC; Villani O; Del Vecchio L; Musto P
J Clin Oncol; 2012 Nov; 30(32):e327-30. PubMed ID: 23008321
[No Abstract] [Full Text] [Related]
9. Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.
Serpa M; Bendit I; Seguro F; Xavier F; Cavalcante M; Steinbaum D; Nardinelli L; Aldred VL; de Paula HM; Dorlhiac-Llacer PE
Acta Haematol; 2010; 124(2):105-9. PubMed ID: 20720403
[TBL] [Abstract][Full Text] [Related]
10. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
11. [A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
Hattori H; Kuwayama M; Kotake T; Karasuno T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):333-6. PubMed ID: 21368508
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
13. Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
Chen Y
Leuk Res; 2011 Jan; 35(1):27-9. PubMed ID: 20723974
[No Abstract] [Full Text] [Related]
14. Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
Yamaguchi M; Munemoto S; Kasada A; Murata R; Ueda M
Leuk Res; 2010 Sep; 34(9):e237-9. PubMed ID: 20371117
[No Abstract] [Full Text] [Related]
15. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
Cea M; Cirmena G; Garuti A; Rocco I; Palermo C; Cagnetta A; Moran E; Colombo N; Grasso R; Fugazza G; Gobbi M; Nencioni A; Ballestrero A; Patrone F
Leuk Res; 2010 Sep; 34(9):e240-2. PubMed ID: 20447687
[No Abstract] [Full Text] [Related]
16. Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
Kuckertz M; Patz M; Veldurthy A; Gehrke I; Claasen J; Frenzel LP; Wendtner CM; Hallek M; Krause G
Onkologie; 2012; 35(7-8):420-6. PubMed ID: 22846973
[TBL] [Abstract][Full Text] [Related]
17. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.
Wickremasinghe RG; Prentice AG; Steele AJ
Leukemia; 2011 Sep; 25(9):1400-7. PubMed ID: 21566651
[TBL] [Abstract][Full Text] [Related]
18. Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate.
Yoon JY; Kumar R; Aloyz R; Johnston JB
Leuk Res; 2011 Sep; 35(9):e179-80. PubMed ID: 21802141
[No Abstract] [Full Text] [Related]
19. How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance.
Zenz T; Häbe S; Denzel T; Winkler D; Döhner H; Stilgenbauer S
Leukemia; 2008 Dec; 22(12):2257-8. PubMed ID: 18480836
[No Abstract] [Full Text] [Related]
20. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Martin SE; Sausen M; Joseph A; Kingham BF
Cancer Genet Cytogenet; 2010 Sep; 201(2):133-4. PubMed ID: 20682399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
